Henry Xiong

2.6k total citations
20 papers, 1.1k citations indexed

About

Henry Xiong is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Henry Xiong has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Henry Xiong's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Genomics and Diagnostics (5 papers). Henry Xiong is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Genomics and Diagnostics (5 papers). Henry Xiong collaborates with scholars based in United States, Brazil and Japan. Henry Xiong's co-authors include James L. Abbruzzese, Robert A. Wolff, Steffan T. Nawrocki, David J. McConkey, Gauri Varadhachary, Maria Simona Pino, Darren W. Davis, Gauri R. Varadhachary, Christopher H. Crane and Douglas B. Evans and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Henry Xiong

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henry Xiong United States 11 769 342 303 239 228 20 1.1k
Shin-ichi Aishima Japan 17 445 0.6× 489 1.4× 302 1.0× 498 2.1× 102 0.4× 20 1.1k
Susanna V. Ulahannan United States 17 524 0.7× 324 0.9× 192 0.6× 106 0.4× 217 1.0× 89 1.1k
Maarten W. Nijkamp Netherlands 17 419 0.5× 346 1.0× 126 0.4× 291 1.2× 119 0.5× 51 1.1k
Kim A. Reiss United States 19 971 1.3× 452 1.3× 226 0.7× 147 0.6× 189 0.8× 63 1.4k
Bunzo Nakata Japan 16 667 0.9× 344 1.0× 201 0.7× 245 1.0× 101 0.4× 70 977
Weikai Xiao China 18 477 0.6× 425 1.2× 265 0.9× 114 0.5× 122 0.5× 37 1.1k
Vanja Vaccaro Italy 15 780 1.0× 491 1.4× 312 1.0× 124 0.5× 89 0.4× 30 1.2k
A. Kalykaki Greece 16 934 1.2× 218 0.6× 387 1.3× 126 0.5× 51 0.2× 52 1.2k
Rong-Zhen Luo China 20 274 0.4× 737 2.2× 230 0.8× 216 0.9× 134 0.6× 40 1.2k
Sherry J. Lim United States 12 674 0.9× 564 1.6× 140 0.5× 244 1.0× 48 0.2× 17 1.2k

Countries citing papers authored by Henry Xiong

Since Specialization
Citations

This map shows the geographic impact of Henry Xiong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Xiong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Xiong more than expected).

Fields of papers citing papers by Henry Xiong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Xiong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Xiong. The network helps show where Henry Xiong may publish in the future.

Co-authorship network of co-authors of Henry Xiong

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Xiong. A scholar is included among the top collaborators of Henry Xiong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Xiong. Henry Xiong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sankhala, Kamalesh K., Chris H. Takimoto, Alain C. Mita, et al.. (2018). Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Investigational New Drugs. 37(1). 76–86. 1 indexed citations
3.
Hurwitz, Herbert I., Benjamin Tan, James A. Reeves, et al.. (2018). Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). The Oncologist. 24(7). 921–932. 48 indexed citations
4.
5.
6.
Fogelman, David R., Mehrdad Jafari, Gauri R. Varadhachary, et al.. (2011). Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology. 68(6). 1431–1438. 21 indexed citations
7.
Javle, Milind, Rachna T. Shroff, Henry Xiong, et al.. (2010). Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 10(1). 368–368. 141 indexed citations
8.
Javle, M. M., Henry Xiong, Sujan Reddy, et al.. (2009). Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. Journal of Clinical Oncology. 27(15_suppl). 4621–4621. 7 indexed citations
9.
Sankhala, Kamalesh K., Chris H. Takimoto, Akira Mita, et al.. (2008). Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. Journal of Clinical Oncology. 26(15_suppl). 2577–2577. 3 indexed citations
10.
Varadhachary, Gauri R., Robert A. Wolff, Christopher H. Crane, et al.. (2008). Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology. 26(21). 3487–3495. 346 indexed citations
11.
Overman, Michael J., Scott Kopetz, Gauri Varadhachary, et al.. (2008). Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors. Cancer Investigation. 26(8). 794–799. 53 indexed citations
12.
Overman, Michael J., Gauri Varadhachary, Scott Kopetz, et al.. (2008). Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Investigational New Drugs. 26(5). 445–454. 67 indexed citations
13.
Wilson, Wyndham H., M. S. Czuczman, Ann S. LaCasce, et al.. (2008). A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Journal of Clinical Oncology. 26(15_suppl). 8511–8511. 27 indexed citations
14.
Phan, Alexandria T., Chris H. Takimoto, Leslie Wood, et al.. (2007). Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors.. Molecular Cancer Therapeutics. 6. 8 indexed citations
15.
Hoff, Paulo M., Robert A. Wolff, Henry Xiong, et al.. (2006). Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer. 106(10). 2241–2246. 8 indexed citations
16.
Nawrocki, Steffan T., Jennifer S. Carew, Maria Simona Pino, et al.. (2006). Aggresome Disruption: A Novel Strategy to Enhance Bortezomib-Induced Apoptosis in Pancreatic Cancer Cells. Cancer Research. 66(7). 3773–3781. 193 indexed citations
17.
Murthy, Ravi, Henry Xiong, Rodolfo Núñez, et al.. (2005). Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results. Journal of Vascular and Interventional Radiology. 16(7). 937–945. 116 indexed citations
18.
Pino, Maria Simona, et al.. (2005). Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biology & Therapy. 4(11). 1263–1269. 34 indexed citations
19.
Pacey, Simon, Mark J. Ratain, Henry Xiong, et al.. (2004). 382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study. European Journal of Cancer Supplements. 2(8). 114–115. 1 indexed citations
20.
Raut, Chandrajit P., Steffan T. Nawrocki, Laura M. Lashinger, et al.. (2004). Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biology & Therapy. 3(12). 1217–1224. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shin-ichi Aishima Breakdown of academic impact, for papers by Susanna V. Ulahannan Breakdown of academic impact, for papers by Maarten W. Nijkamp Breakdown of academic impact, for papers by Kim A. Reiss Breakdown of academic impact, for papers by Bunzo Nakata Breakdown of academic impact, for papers by Weikai Xiao Breakdown of academic impact, for papers by Vanja Vaccaro Breakdown of academic impact, for papers by A. Kalykaki Breakdown of academic impact, for papers by Rong-Zhen Luo Breakdown of academic impact, for papers by Sherry J. Lim
Rankless by CCL
2026